Contact
searchSearch
HMP Global
Login

Breast Cancer

Breast Cancer
Specialty Channel
FDA Approval
FDA Approves Sacituzumab Govitecan for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
06/24/2026
Emily Estrada
Based on results from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, the FDA has approved sacituzumab govitecan for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer as...
Based on results from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, the FDA has approved sacituzumab govitecan for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer as...
Based on results from the...
06/24/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology
Kevin Kalinsky, MD
Videos
Frontline Sacituzumab Govitecan Continues to Show Benefit in PD-L1–Positive Triple-Negative Breast Cancer
06/24/2026
Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...
Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...
Kevin Kalinsky, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Pembrolizumab Demonstrates Long-Term Survival Benefit in in Early-Stage Triple-Negative Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses final results from the KEYNOTE-522 study showing durable event-free and overall survival benefits with pembrolizumab plus chemotherapy in patients with stage 2/3 triple-negative breast cancer, confirming its...
Peter Schmid, MD, PhD, discusses final results from the KEYNOTE-522 study showing durable event-free and overall survival benefits with pembrolizumab plus chemotherapy in patients with stage 2/3 triple-negative breast cancer, confirming its...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology
FDA Approval
FDA Approves Palbociclib-Based Maintenance for Patients With HR-Positive, HER2-Positive Advanced Breast Cancer
06/24/2026
Emily Estrada
Based on results from the 3 PATINA trial, the FDA has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for patients with HR-positive, HER2-positive locally...
Based on results from the 3 PATINA trial, the FDA has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for patients with HR-positive, HER2-positive locally...
Based on results from the 3...
06/24/2026
Oncology
Robert Stein, PhD
Videos
Prosigna-Guided Treatment Safely Reduces Chemotherapy Use in HR-Positive, HER2-Negative Early Breast Cancer
06/19/2026
Robert Stein, PhD
Robert Stein, PhD, discusses results from the phase 3 OPTIMA trial showing that Prosigna-guided treatment identified approximately 68% of patients with HR-positive, HER2-negative early breast cancer who could safely avoid chemotherapy without...
Robert Stein, PhD, discusses results from the phase 3 OPTIMA trial showing that Prosigna-guided treatment identified approximately 68% of patients with HR-positive, HER2-negative early breast cancer who could safely avoid chemotherapy without...
Robert Stein, PhD, discusses...
06/19/2026
Oncology
Sara Tolaney, MD
Videos
Sacituzumab Govitecan Plus Pembrolizumab Delivers Benefit Independent of TROP2 Expression in Triple-Negative Breast Cancer
06/19/2026
Sara Tolaney, MD
Sara Tolaney, MD, discusses biomarker analysis results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab improved progression-free survival regardless of TROP2 expression, BRCA mutation status, or HER2 expression...
Sara Tolaney, MD, discusses biomarker analysis results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab improved progression-free survival regardless of TROP2 expression, BRCA mutation status, or HER2 expression...
Sara Tolaney, MD, discusses...
06/19/2026
Oncology
Mabel Mardones, MD
Videos
Giredestrant Demonstrates Favorable Safety Profile but Fails to Significantly Improve PFS in HR-Positive, HER2-Negative Metastatic Breast Cancer
06/18/2026
Mabel Mardones, MD
Mabel Mardones, MD, discusses results from the phase 3 persevERA trial which showed that giredestrant plus palbociclib achieved a numerical progression-free survival improvement over letrozole plus palbociclib but did not meet the study’s...
Mabel Mardones, MD, discusses results from the phase 3 persevERA trial which showed that giredestrant plus palbociclib achieved a numerical progression-free survival improvement over letrozole plus palbociclib but did not meet the study’s...
Mabel Mardones, MD, discusses...
06/18/2026
Oncology
Oleg Gluz, MD
Videos
Longer Docetaxel-Based Chemotherapy Associated With Improved Outcomes in High-Risk HR-Positive, HER2-Negative Breast Cancer
06/11/2026
Oleg Gluz, MD
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled...
06/11/2026
Oncology
News
Omitting Axillary Lymph Node Dissection Appears Safe in Node-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC...
05/30/2026
Oncology

News

News
Omitting Axillary Lymph Node Dissection Appears Safe in Node-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC...
05/30/2026
Oncology
Hope Rugo, MD
Videos
Advancing Vaccine Approaches in Triple-Negative Breast Cancer
05/30/2026
Hope Rugo, MD, discusses results from a phase 3 trial evaluating adagloxad simolenin in patients with high-risk early-stage triple-negative breast cancer.
Hope Rugo, MD, discusses results from a phase 3 trial evaluating adagloxad simolenin in patients with high-risk early-stage triple-negative breast cancer.
Hope Rugo, MD, discusses results...
05/30/2026
Oncology
FDA Approval
FDA Approves Datopotamab Deruxtecan for Patients With Triple-Negative Breast Cancer
05/22/2026
Emily Estrada
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the...
05/22/2026
Oncology
News
Ipatasertib Plus Fulvestrant and Palbociclib Shows Strong Preliminary Activity in HR-Positive, HER2-Negative Breast Cancer
05/21/2026
Stephanie Holland
Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...
Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...
Clinical...
05/21/2026
Oncology
FDA Approval
FDA Approves Neoadjuvant and Adjuvant T-DXd for Patients With HER2-Positive Early Breast Cancer
05/18/2026
Stephanie Holland
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Based on results from the phase...
05/18/2026
Oncology
News
BTX-9341 Shows Promising Efficacy, Safety in HR-Positive, HER2-Negative Advanced Breast Cancer
05/15/2026
Emily Estrada
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1...
05/15/2026
Oncology
News
pCR Guided Chemotherapy De-Escalation Shows Promise in HER2-Positive Early Breast Cancer
05/15/2026
Emily Estrada
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided...
05/15/2026
Oncology
News
Tucatinib Plus T-DM1 Shows Sustained Disease Control in HER2-Positive Advanced Breast Cancer
05/13/2026
Emily Estrada
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3...
05/13/2026
Oncology
News
Trastuzumab Deruxtecan Plus Paclitaxel, Trastuzumab, and Pertuzumab Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer
05/11/2026
Stephanie Holland
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from...
05/11/2026
Oncology
News
Sacituzumab Govitecan Plus Trastuzumab Showed Limited Activity After T-DXd in HER2-Positive Metastatic Breast Cancer
05/11/2026
Stephanie Holland
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the...
05/11/2026
Oncology

Interactive Features

FDA Alerts
Camizestrant Fails to Gain Support from the FDA’s Advisory Committee in ESR1-Mutated Advanced Breast Cancer
05/07/2026
Stephanie Holland
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the...
05/07/2026
Oncology
Quiz
Niraparib Plus Dostarlimab for Patients With Germline BRCA1/2-Mutated TNBC
12/11/2025
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC...
12/11/2025
Oncology
Quiz
Novel Antibody-Drug Conjugate MRG002 Payload
09/25/2025
Do you know the payload for the novel antibody-drug conjugate MRG002? Take our quick quiz to find out!
Do you know the payload for the novel antibody-drug conjugate MRG002? Take our quick quiz to find out!
Do you know the payload for the...
09/25/2025
Oncology
Quiz
ADC Performance in HR-Positive, HER2-Negative Metastatic Breast Cancer
08/21/2025
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know the clinical impact...
08/21/2025
Oncology
Quiz
Intracranial Activity of Trastuzumab Deruxtecan Among Patients With HER2-Low Metastatic Breast Cancer With Active Brain Metastases
08/07/2025
Do you know what the intracranial activity of trastuzumab deruxtecan was among patients with HER2-low metastatic breast cancer with active brain metastases? Test your knowledge with our quiz!
Do you know what the intracranial activity of trastuzumab deruxtecan was among patients with HER2-low metastatic breast cancer with active brain metastases? Test your knowledge with our quiz!
Do you know what the...
08/07/2025
Oncology
Quiz
Results From the Biomarker Analysis of DESTINY-Breast06
07/31/2025
Do you know what the findings were from the exploratory biomarker analysis of DESTINY-Breast06 were? Take our quick quiz to find out!
Do you know what the findings were from the exploratory biomarker analysis of DESTINY-Breast06 were? Take our quick quiz to find out!
Do you know what the findings...
07/31/2025
Oncology
Quiz
AI Assistance for Immunohistochemistry Assessment of Breast Cancer
06/13/2025
06/13/2025
Oncology
Quiz
First-Line Administration of Subtype-Based Therapy for Patients With Previously Untreated, Metastatic/Recurrent Triple-Negative Breast Cancer
02/02/2024
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the...
02/02/2024
Oncology
Quiz
Quiz: Are All CDK4/6 Inhibitors Created Equal?
12/15/2022
How did CDK4/6 inhibitor palbociclib impact overall survival in patients with ER+/HER2- breast cancer?
How did CDK4/6 inhibitor palbociclib impact overall survival in patients with ER+/HER2- breast cancer?
How did CDK4/6 inhibitor...
12/15/2022
Oncology
Quiz
Quiz: Breast Cancer Subtypes With Differing Times to Recurrence
12/15/2022
Was the time-to-recurrence better for patients with ER-positive/HER2-negative breast cancer with the HER-2E biomarker compared to those without?
Was the time-to-recurrence better for patients with ER-positive/HER2-negative breast cancer with the HER-2E biomarker compared to those without?
Was the time-to-recurrence...
12/15/2022
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use